Homocysteine concentrations and vascular complications in patients with type 2 diabetes

Diabetes and Metabolism

Volumn 31, Issue 2, 2005, Pages 112-117

  Rudy, A ^a   Kowalska, I ^a   Straczkowski M ^a   Kinalska, I ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Diabetes; Diabetic complications; Homocysteine

Indexed keywords

CREATININE; CYANOCOBALAMIN; FOLIC ACID; GLIMEPIRIDE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; TROGLITAZONE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHRONIC DISEASE; CLINICAL EXAMINATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION COEFFICIENT; CREATININE BLOOD LEVEL; DIABETIC ANGIOPATHY; DIABETIC DIET; FOLIC ACID BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; HYPERHOMOCYSTEINEMIA; ISCHEMIC HEART DISEASE; LIPID METABOLISM; MAJOR CLINICAL STUDY; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; VITAMIN BLOOD LEVEL;

EID: 17744389242     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)70176-3     Document Type: Article

References (36)

1. Wetterhall SF, Olson DR, DeStefano F, et al. Trends in diabetes and diabetic complications 1980-1987. Diabetes Care, 1992, 15, 960-7.
2. Stratton IM, Adler AI, Neil W, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. B Med J, 2000, 321, 405-12.
3. McCully KS. Vascular Pathology of Homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol, 1969, 56, 111-28.
4. DeBree A, Verschuren M, Kromhout D, Kluitmans LA, Bloom HJ. Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. Pharmacol Rev, 2002, 54, 599-618.
5. Welch GN, Loscalzo J. Homocysteine nd atherothormbosis. N Eng J Med, 1998, 338, 1042-50.
6. McCully KS. Homocysteine and vascular disease. Nat Med, 1996, 2, 386-9.
7. Nygard O, Nordehang JE. Plasma Homocysteine Levels and mortality in Patients with Coronry Artery Disease. N Engl J Med, 1997, 337, 230-7.
8. Soinio M, Marniemi J, Laakso M, Lehto S, Ronnemaa T. Elevated plasma homocysteine level is an independent predictor of coronary heart disease events in patients with type 2 diabetes mellitus. Ann Intern Med, 2004, 140, 94-100.
9. Tofler GH, D-Agostino RB, Jacques PF, Bostom AG, Wilson PW, Lipinska I, Mittleman MA, Selhub J. Association between increased homocysteine levels and impaired fibrinolytic potential:potential mechanism for cardiovascular risk. Thromb Haemost, 2002, 88, 799-804.
10. Mangoni A, Jackson SH. Homocysteine and Cardiovascular Disease: Current Evidence and Future Prospects. Am J Med, 2002, 112, 556-65.
11. Friedman AN, Andrew G. The kidney and homocysteine metabolism. J Am Soc Nephro, 2001, 12, 2181-9.
12. Aso Y, Yoshida N, Okumura K, et al. Coagulation and inflammation in overt diabetic nephropathy: association with hyperhomocysteinemia. Clin Chim Acta, 2004, 348, 139-45.
13. Fonseca V, Guba SC, Fink LM. Hyperhomocysteinemia and the Endocrine System: Implications for Atherosclerosis and Thrombosis. Endocrine Rev, 1999, 20, 738-59.
14. Schnyder G, Riccardo P. Association of Plasma Homocysteine with the number of Major Coronary Arteries Severly Narrowed. Am J Cardiol, 2001, 88, 1027-30.
15. Stehouwer CD, Gall MA. Plasma homocysteine concentration predicts mortality in non-insulin dependent diabetic patients with and without albuminuria. Kidney Int, 1999, 55, 308-14.
16. Hoogeven EK, Kostense PJ, Beks PJ, et al. Hyperhomocysteinemia is associated with an increased Risk of Cardiovascular Disease, Especially in Non-Insulin Dependent Diabetes Mellitus. Arterio Thromb Vasc Biol, 1998, 18, 133-8.
17. Hoogeven EK, Kostense PJ, Beks PJ, et al. Hyperhomocysteinemia Increases Risk of death Especially in type 2 Diabetes. Circulation, 2000, 101, 1506-10.
18. Coppola A, Astarita C, Oliviero M, et al. Impairment of coronary circulation by acute hyperhomocysteinemia in type 2 diabetic patients. Diabetes Care, 2004, 27, 2055-6.
19. Meigs JB, Jacques PF, Selhub J, et al. Fasting Plasma Homocysteine Levels in the Insulin Resistance Syndrome. Diabetes Care, 2001, 24, 1403-10.
20. Okada E, Oida K, Tada H, Asazuma K. Hyperhomocysteinemia is a risk factor for coronbary arteriosclerosis in Japanese patients with type 2 diabetes. Diabetes Care, 1999, 22, 484-90.
21. Kark JD, Selhub J, Bostom A, Adler B, Rosenberg IH. Plasma Homocysteine and all-cause mortality in diabetes. Lancet, 1999, 353, 1936-7.
22. Sundstrom J, Sullivan L, D'Agostino RB et al. Plasma homocysteine, hypertension incidence, and blood pressure tracking: the Framingham Heart Study. Hypertension, 2003, 42, 1100-5.
23. Buysschaert M, Dramais AS, Wallemacq PE, Hermans MP. Hyperhomocysteinemia in type 2 diabetes:relationship to macroangiopathy, nephropathy, and insulin resistance. Diabetes Care, 2000, 12, 1816-22.
24. Davies L, Williamhurst EG, McElduff A, Gunton J, Clifton-Bligh R Fulcher G. The Relationship among Homocysteine, Creatinine Clearance and Albuminuria in Patients with Type 2 Diabetes. Diabetes Care, 2001, 24, 1805-9.
25. Smulders YM, Rakic M, Slaats EH. Fasting and post-methionine homocysteine levels in NIDDM. Determinants and Correlations with retinopathy, albuminuria and cardiovascular disease. Diabetes Care, 1999, 22, 125-32.
26. Saltzman E, Mason JB, Jacues PF. B vitamin supplementation lowers homocysteine levels in heart disease. Clin Res, 1994, 42, 172A.
27. Mooradian AD, Failla M, Hoogwerf B, Maryniuk M, Wylie-Rosett J. Selected vitamins and minerals in diabetes. Diabetes Care, 1994, 17, 464-79.
28. Nurk E, Tell GS, Vollset SE, et al. Changes in lifestyle and plasma total homocysteine: the Hordaland Homocysteine Study. Am J Clin Nutr, 2004, 79, 812-9.
29. Drzewoski J, Czupryniak L, Chwatko G, Bald E. Total plasma homocysteine levels in type 2 diabetic patients with secondary failure to oral agents. Diabetes Care, 2001, 22, 2097-99.
30. Drzewoski J, Czupryniak L, Chwatko G, Bald E. Hyperhomocysteinemia in poorly controlled type 2 diabetes patients. Diabetes Nutr Metab, 2000, 13, 312-24.
31. Derosa G, Franzetti I, Gadaleta G, Ciccarelli L, Fogari R. Metabolic variations with oral antidiabetic drugs in patients with type 2 diabetes:comparison between glimepiryde and metformin. Diabetes Nutr Metab, 2004, 17, 143-50.
32. Hoogeven EK, Kostense PJ, Jakobs C, Bouter LM, Heine RJ, Stehouwer CDA. Does metformin increase the serum total Homocysteine level in Non Insulin Dependent Diabetes Mellitus? J Intern Med, 1997, 242, 389-94.
33. Fonseca V, Keebler M, Dicker-Brown A, et al. The effect of troglitazone on plasma homocysteine, hepatic and red blood cell S-adenosyl methionine, and S-adenosyl homocysteine and enzymes in homocysteine metabolism in Zucker rats. Metabolism, 2002, 51, 783-6.
34. Robinson K. Homocysteine, B vitamins, and risk of cardiovascular disease. Heart, 2000, 83, 127-30.
35. Setola E, Monti LD, Galluccio E, et al. Insulin resistance and endothelial function are improved after folate and vitamin B12 therapy in patients with metabolic syndrome: relationship between homocysteine levels and hyperinsulinemia. Eur J Endocrinol, 2004, 151, 483-9.
36. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA, 1995, 274, 1049-51.